L.Y. Dirix, MD, University of Antwerp, Belgium, discussed the
suppression of tumor growth and metastases by disrupting blood
vessels. Angiogenesis inhibitors and vascular targeting agents
show promise in treating cancer and other diseases. (See the
related reports of Chaplin and Vermeulen in this
issue of Conrad Notes).
|The role of angiogenesis in disease||
Folkman provided a comprehensive review of blood vessel
formation in cancer and other diseases (Nature Med 1995;1:27-31).
Excessive angiogenesis also occurs in rheumatoid arthritis,
psoriasis, duodenal ulcers, and hemangioma.
Folkman described several key chemicals and activities in angiogenesis:
|Modulating angiogenesis by treatment||
Two type of agents counteract angiogenesis. One group inhibits
the process and the other targets blood vessels. The blockers
interfere with endothelial cells in the beginning by degrading
the basal membrane. Later, the inhibitors disrupt cell
migration, proliferation, and tubule formation.
Vascular-targeting chemicals selectively destroy tumor blood vessels. The resultant decrease in tumor metabolism leads to shrinkage and necrosis.
|Inhibiting the angiogenesis process||
Phase II clinical studies are in progress with the following
|Vascular targetting treatments||The agent CM 101 binds to tumor endothelium, activates complement, and causes selective tumor vessel damage. These actions result in rapid tumor necrosis. Other chemicals in this group are combrestatin A-4 (COA-4) and its soluble prodrug. Both bind to tubulin and cause endothelial cell damage, according to Chaplin.|
Presented at The European Cancer Conference (ECCO 9), September
Copyright © 1997 Conrad Group, Inc. All Rights Reserved
Eugene A. Conrad, PhD, MPH / ISSN 1078-2230 / November 1997
Send comments to: ConradNote@aol.com